Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
29. Januar 2019 07:00 ET
|
Voyager Therapeutics, Inc.; Neurocrine Biosciences, Inc.
Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine Biosciences gains...
Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
07. November 2018 16:10 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s Disease
09. März 2018 07:02 ET
|
Voyager Therapeutics, Inc.
Robust and durable improvements in patients' motor function achieved with substantial reductions in use of daily oral levodopa and other Parkinson’s disease medications; one-time administrations of...